Welcome to our dedicated page for Abivax S.A. SEC filings (Ticker: ABVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Abivax SA (ABVX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. Abivax files reports such as Form 6-K and uses registration statements including Form F-3 and Form S-8 in connection with its capital markets activities. These documents offer insight into Abivax’s clinical progress, financing transactions, and other material developments as it advances obefazimod (ABX464) for chronic inflammatory diseases.
Through its Form 6-K current reports, Abivax has disclosed items such as an underwriting agreement for a public offering of American Depositary Shares under an automatic shelf registration statement on Form F-3, as well as information on major ordinary share transactions and financing arrangements. Filings also reference the company’s universal registration document with the French Autorité des Marchés Financiers and its Annual Report on Form 20-F, which includes a “Risk Factors” section describing key risks and uncertainties.
On this page, you can review real-time updates from EDGAR for Abivax’s U.S. filings, including current reports that discuss public offerings of ADSs, changes in financing structures, and significant clinical trial progress noted in the company’s tagged financial and narrative disclosures. Stock Titan’s tools provide AI-powered summaries that highlight the main points of lengthy filings, helping readers quickly understand the implications of complex documents without reading every section.
In addition to capital markets information, Abivax’s filings can shed light on how the company allocates operating expenses to research and development for its ulcerative colitis and Crohn’s disease programs, as well as on changes in its financial position over time. Use this page to track new 6-K submissions, reference the registration statements that support securities offerings, and connect the company’s regulatory reporting with its clinical and corporate news flow.
Abivax SA, a French clinical-stage biopharma listed via ADSs on the Nasdaq Global Market, reports continued heavy losses and remains pre-revenue. For the year ended December 31, 2025, net loss widened to €336.1 million, following losses of €176.2 million in 2024 and €147.7 million in 2023.
The company is highly dependent on its lead candidate obefazimod for inflammatory bowel diseases, with all other programs at earlier stages and no approved products. Abivax carried forward €912.9 million of tax losses as of December 31 2025 and booked a €3.1 million French R&D tax credit that year.
Material weaknesses in internal control over financial reporting identified in prior years persisted through 2025 across risk assessment, control activities, information and communication, monitoring and control environment, despite ongoing remediation. Potential dilution is significant: 8,857,084 potential new ordinary shares from equity instruments outstanding at December 31 2025, equal to a hypothetical 11.3% dilution, while equity incentive plans represented 9.2% of fully diluted share capital. Ordinary shares outstanding totaled 78,536,412 at year-end 2025.
Abivax reported audited full-year 2025 results, combining a large capital raise with heavier investment and losses as it advances obefazimod toward late-stage milestones. The company completed a U.S. underwritten public offering raising net proceeds of approximately $700.3 million, or about €597.2 million.
Cash, cash equivalents and short-term investments reached €530.4 million as of December 31, 2025, supporting a projected cash runway into Q4 2027. Abivax settled substantially all debt with Kreos, Claret and Heights, sharply reducing borrowings to €1.9 million while increasing royalty certificate liabilities to €30.2 million.
R&D expenses rose to €177.8 million, mainly from Phase 3 ulcerative colitis and Phase 2b Crohn’s disease trials for obefazimod and related CMC and new indication work. G&A expenses more than doubled to €67.7 million, driven largely by share-based compensation and related employer taxes. Net loss widened to €336.1 million.
A March 18, 2026 DSMB review of the ABTECT-UC Phase 3 maintenance trial reported no new safety signals, with nearly 90% of patients completing 44 weeks, and topline results remain expected in late Q2 2026. Abivax strengthened its leadership bench with a new Chief Commercial Officer and senior regulatory and research hires, while its Chief Scientific Officer departs after 17 years.
Abivax SA filed a Form 6-K summarizing extensive new data on its lead candidate obefazimod in inflammatory bowel disease, including 22 abstracts presented at ECCO 2026. Preclinical models showed first evidence of anti-fibrotic activity, with large reductions in fibrosis and inflammation markers under early and late treatment.
A pooled safety analysis from the Phase 3 ABTECT induction trials reported serious treatment emergent adverse event and discontinuation rates similar to placebo across 1,272 patients, with mostly mild, short-lived headaches. Clinical data showed symptomatic response from week 1 and symptomatic remission from week 2, alongside increased miR-124 expression and reduced IL-17A and IL-6 levels. The company highlighted upcoming Phase 3 maintenance trial results expected in Q2 2026 and Phase 2b ENHANCE-CD trial results expected in Q4 2026.
Abivax S.A. received an updated ownership report from Invus Public Equities and related entities, which together may be deemed to beneficially own 3,922,995 Ordinary Shares as of December 31, 2025. This stake represents 5.0% of Abivax’s ordinary shares, based on 77,830,067 shares outstanding as of September 30, 2025.
The filing explains the control chain: Invus Public Equities directly holds the shares, with Invus Public Equities Advisors, Invus Global Management, Siren, L.L.C., and individual Raymond Debbane each potentially deemed beneficial owners through their respective roles. The report notes that the CUSIP 00370M103 applies to Abivax American Depositary Shares, each representing one Ordinary Share.
The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Abivax, but as a passive investment under the applicable SEC rules.
Abivax S.A. shareholder Sofinnova Crossover I SLP and affiliated reporting persons update their ownership after selling American depositary shares in the market. On January 12 and 13, 2026, Sofinnova Crossover I SLP sold multiple blocks of Abivax ADSs in open‑market transactions at weighted average prices ranging from $118.27 to $141.26 per ADS, plus a separate trade of 100 ADS at $142.00 per ADS.
As of January 14, 2026, Sofinnova Crossover I SLP holds 3,334,739 Ordinary Shares, representing about 4.3% of Abivax’s 78,398,795 Ordinary Shares outstanding as of November 30, 2025. These shares carry 6,399,478 voting rights, or 7.7% of the 82,688,932 voting rights outstanding. The management company Sofinnova Partners SAS and investment committee members may be deemed to share voting and investment control, although the individuals disclaim beneficial ownership except for their pecuniary interests.
ABVX shareholder Sofinnova Crossover I SLP has filed a notice of proposed sale under Rule 144 covering 1,000,000 ADS, to be sold through Leerink Partners on the NASDAQ. The filing lists an aggregate market value of 133700000.00 for these shares and an approximate sale date of 01/08/2026.
The ADS were originally acquired in a private placement from the issuer on 07/11/2019, with cash payment completed on 07/15/2019. The filing also notes that securities of the same issuer were sold in the prior three months: 590,877 ADS on 10/28/2025 for gross proceeds of 55638897.00, and 609,123 ADS on 10/29/2025 for gross proceeds of 57261354.00. Shares outstanding are shown as 77,800,000 ADS, providing context for the size of the planned sale.
Venrock-affiliated funds filed Amendment No. 2 to Schedule 13G reporting a passive stake in Abivax SA (ABVX). The group reported beneficial ownership of 576,729 ordinary shares in the form of ADSs, representing 0.8% of the class as of September 30, 2025.
The holdings comprise 151,622 ADSs by VHCP III, 15,167 ADSs by VHCP Co-Investment III, and 409,940 ADSs by VHCP EG. Each ADS represents one ordinary share. The percentage was calculated against 73,574,749 ordinary shares outstanding as of July 28, 2025, per the issuer’s prospectus supplement. The reporting persons disclose shared voting and dispositive power over 576,729 shares and no sole power. They certified the securities were not acquired to change or influence control.
Abivax SA (ABVX): Schedule 13G/A filed reporting passive ownership by TCG Crossover affiliates and Chen Yu. The filing lists 7,111,596 Abivax ADSs beneficially owned by Chen Yu, equal to 9.1% of the ordinary shares. TCG Crossover Fund I holds 6,456,596 ADSs (8.3%), and TCG Crossover Fund II holds 655,000 ADSs (0.8%).
Each ADS represents one ordinary share. Percentages are based on 77,830,067 ordinary shares outstanding as of September 30, 2025. The reporting persons disclaim group status and certify the securities were not acquired to change or influence control.
Abivax SA (ABVX) — Schedule 13D/A Amendment No. 3: Sofinnova Crossover I SLP and affiliated reporting persons updated their ownership and disclosed recent open‑market sales of American Depositary Shares. As of September 30, 2025, they report holding 4,334,739 Ordinary Shares, representing approximately 5.6% of shares outstanding, and 8,399,478 voting rights, representing approximately 9.4% of voting rights. The base figures cited are 77,830,067 Ordinary Shares and 89,189,666 voting rights outstanding as of September 30, 2025.
The filing lists sales completed in multiple transactions: on October 28, 2025, 522,948 ADSs at a weighted average price of $94.00 per share and 67,929 ADSs at a weighted average price of $95.42; on October 29, 2025, 606,293 ADSs at a weighted average price of $94.00 and 2,830 ADSs at a weighted average price of $95.34. The reporting persons state the shares were acquired for investment purposes and reserve the right to buy or sell as permitted by law.
ABVX: A stockholder filed a Form 144 to sell up to 1,200,000 ADS, with an aggregate market value of $111,300,000. The proposed sale is listed for approximately 10/28/2025 through Leerink Partners on the NASDAQ.
The securities were acquired in the IPO on 10/20/2023, with 1,200,000 ADS purchased from the issuer and paid in cash on 10/24/2023. Shares outstanding were 77,800,000; this is a baseline figure, not the amount being offered.